The Journal of Nutritional Biochemistry
Volume 16, Issue 8 , Pages 449-466 , August 2005

Resveratrol as an anticancer nutrient: molecular basis, open questions and promises

Received 17 September 2004 ,Revised 11 January 2005 ,Accepted 20 January 2005.

References 

  1. Langcake P, Pryce RJ. A new class of phytoalexins from grapevines. Experientia. 1977;33:151–152
  2. Dixon RA. Natural products and plant disease resistance. Nature. 2001;411:843–847
  3. Nakaune R, Hamamoto H, Imada J, Akutsu K, Hibi T. A novel ABC transporter gene, PMR5, is involved in multidrug resistance in the phytopathogenic fungus Penicillium digitatum. Mol Genet Genomics. 2002;267:179–185
  4. Heath MC. Nonhost resistance and nonspecific plant defenses. Curr Opin Plant Biol. 2000;3:315–319
  5. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J. 2003;374:157–163
  6. Sanders TH, McMichael RW, Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 2000;48:1243–1246
  7. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 2004;52:4713–4719
  8. Matsuda H, Tomohiro N, Hiraba K, Harima S, Ko S, Matsuo K, et al. Study on anti-Oketsu activity of rhubarb II. Anti-allergic effects of stilbene components from Rhei undulati Rhizoma (dried rhizome of Rheum undulatum cultivated in Korea). Biol Pharm Bull. 2001;24:264–267
  9. Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-J O-Kon. (Polygonum cuspidatum Sieb Et Zucc.). Yakugaku Zasshi. 1963;83:988–990
  10. Hathway DE. The use of hydroxystilbene compounds as taxonomic tracers in the genus Eucalyptus. Biochem J. 1962;83:80–84
  11. Oleszek W, Sitek M, Stochmal A, Piacente S, Pizza C, Cheeke P. Resveratrol and other phenolics from the bark of Yucca schidigera roezl. J Agric Food Chem. 2001;49:747–752
  12. Likhitwitayawuid K, Sawasdee K, Kirtikara K. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri. Planta Med. 2002;68:841–843
  13. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220
  14. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–780
  15. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000;130:467S–471S
  16. Fremont L. Biological effects of resveratrol. Life Sci. 2000;66:663–673
  17. Belguendouz L, Fremont L, Gozzelino MT. Interaction of transresveratrol with plasma lipoproteins. Biochem Pharmacol. 1998;55:811–816
  18. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet. 1993;341:454–457
  19. Kerry NL, Abbey M. Red wine and fractionated phenolic compounds prepared from red wine inhibit low density lipoprotein oxidation in vitro. Atherosclerosis. 1997;135:93–102
  20. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med. 2002;9:77–79
  21. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G, et al. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol. 1998;123:1691–1699
  22. Li HF, Chen SA, Wu SN. Evidence for the stimulatory effect of resveratrol on Ca(2+)-activated K+ current in vascular endothelial cells. Cardiovasc Res. 2000;45:1035–1045
  23. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003;64:1029–1036
  24. Pendurthi UR, Rao LV. Resveratrol suppresses agonist-induced monocyte adhesion to cultured human endothelial cells. Thromb Res. 2002;106:243–248
  25. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398
  26. Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, et al. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 2003;163:165–171[discussion 264–166]
  27. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 2001;22:1111–1117
  28. Andlauer W, Kolb J, Siebert K, Furst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res. 2000;26:47–55
  29. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun. 2000;272:212–217
  30. Bertelli A, Bertelli AA, Gozzini A, Giovannin L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res. 1998;24:133–138
  31. Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM. Absorption of trans-resveratrol in rats. Methods Enzymol. 2001;335:145–154
  32. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med. 2002;33:387–398
  33. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002;302:369–373
  34. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72:2219–2233
  35. Kaldas MI, Walle UK, Walle T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol. 2003;55:307–312
  36. Lancon A, Delma D, Osman H, Thenot JP, Jannin B, Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun. 2004;316:1132–1137
  37. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36:79–87
  38. Krasnow MN, Murphy TM. Polyphenol glucosylating activity in cell suspensions of grape (Vitis vinifera). J Agric Food Chem. 2004;52:3467–3472
  39. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett. 1998;436:71–75
  40. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004;52:935–942
  41. Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom. 2003;17:307–313
  42. de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 2000;30:1047–1054
  43. Manzocco L, Calligaris S, Nicoli MC. Assessment of pro-oxidant activity of foods by kinetic analysis of crocin bleaching. J Agric Food Chem. 2002;50:2767–2771
  44. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem. 2003;46:1081–1111
  45. Davis SR, Dalais FS, Simpson ER, Murkies AL. Phytoestrogens in health and disease. Recent Prog Horm Res. 1999;54:185–210[discussion 210–181]
  46. Ganry O. Phytoestrogen and breast cancer prevention. Eur J Cancer Prev. 2002;11:519–522
  47. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE, et al. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer. 2003;104:587–596
  48. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A. 1997;94:14138–14143
  49. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, et al. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol. 2004;88:223–234
  50. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3:1041–1064
  51. Mgbonyebi OP, Russo J, Russo IH. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol. 1998;12:865–869
  52. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999;179:297–304
  53. Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 2001;61:6137–6144
  54. Narayanan BA, Narayanan NK, Stoner GD, Bullock BP. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002;70:1821–1839
  55. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999;59:5892–5895
  56. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002;62:2488–2492
  57. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF, Mabry TJ. Flavonoid effects relevant to cancer. J Nutr. 2002;132:3482S–3489S
  58. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003;111:1651–1664
  59. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000;164:6509–6519
  60. Woo JH, Lim JH, Kim YH, Suh SI, Min do S, Chang JS, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene. 2004;23:1845–1853
  61. Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM, Kong AN. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol. 2001;60:217–224
  62. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer. 2004;91:178–185
  63. Coleman KM, Smith CL. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci. 2001;6:D1379–D1391
  64. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, et al. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem. 2000;78:429–441
  65. El-Mowafy AM, Alkhalaf M. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis. 2003;24:869–873
  66. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003;42:153–178
  67. Marchand A, Barouki R, Garlatti M. Regulation of NAD(P)H:quinone oxidoreductase 1 gene expression by CYP1A1 activity. Mol Pharmacol. 2004;65:1029–1037
  68. Mikstacka R, Gnojkowski J, Baer-Dubowska W. Effect of natural phenols on the catalytic activity of cytochrome P450 2E1. Acta Biochim Pol. 2002;49:917–925
  69. Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol. 1999;56:760–767
  70. Shou M, Korzekwa KR, Krausz KW, Buters JT, Grogan J, Goldfarb I, et al. Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz[a]anthracene. Mol Carcinog. 1996;17:241–249
  71. Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001;299:874–882
  72. Szaefer H, Cichocki M, Brauze D, Baer-Dubowska W. Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons — DNA adduct formation by plant phenolics in mouse epidermis. Nutr Cancer. 2004;48:70–77
  73. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75:639–653
  74. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol. 1997;17:1846–1858
  75. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3:31–36
  76. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651–4655
  77. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225–230
  78. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol. 1998;113:147–156
  79. Vieira H, Kroemer G. Mitochondria as targets of apoptosis regulation by nitric oxide. IUBMB Life. 2003;55:613–616
  80. Radisavljevic Z. Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J Cell Biochem. 2004;92:1–5
  81. Ohshima H. Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. Toxicol Lett. 2003;140–141:99–104
  82. Xia YF, Liu LP, Zhong CP, Geng JG. NF-kappaB activation for constitutive expression of VCAM-1 and ICAM-1 on B lymphocytes and plasma cells. Biochem Biophys Res Commun. 2001;289:851–856
  83. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R, et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol. 2002;117:842–851
  84. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, Fernandez P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol. 2002;61:294–302
  85. Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 1999;59:2596–2601
  86. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol. 1999;126:673–680
  87. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004;31:64–73
  88. Rouzer CA, Marnett LJ. Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev. 2003;103:2239–2304
  89. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004;279:22727–22737
  90. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235
  91. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003;3:107–112
  92. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003;4:605–615
  93. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  94. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336–3340
  95. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998;273:21875–21882
  96. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272–277
  97. O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res. 2004;551:245–254
  98. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002;62:4945–4954
  99. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116:221–234
  100. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 2001;7:1466–1473
  101. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun. 1998;250:53–58
  102. Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol. 2003;63:925–932
  103. Mnjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun. 2003;311:546–552
  104. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003;102:987–995
  105. Latruffe N, Delmas D, Jannin B, Malki MC, Passilly-Degrace P, Berlot JP. Molecular analysis on the chemopreventive properties of resveratrol, a plant polyphenol microcomponent. Int J Mol Med. 2002;10:755–760
  106. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol. 2002;64:1375–1386
  107. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002;8:893–903
  108. Larrosa M, Tomas-Barberan FA, Espin JC. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem. 2003;51:4576–4584
  109. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene. 2004;23:6702–6711
  110. Liang YC, Tsai SH, Chen L, Lin-Shiau SY, Lin JK. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol. 2003;65:1053–1060
  111. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 1999;254:739–743
  112. Della Ragione F, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V. Antioxidants induce different phenotypes by a distinct modulation of signal transduction. FEBS Lett. 2002;532:289–294
  113. Park JW, Choi YJ, Jang MA, Lee YS, Jun DY, Suh SI, et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett. 2001;163:43–49
  114. Bruder JL, Hsieh T, Lerea KM, Olson SC, Wu JM. Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol. 2001;2:1
  115. Nielsen M, Ruch RJ, Vang O. Resveratrol reverses tumor-promoter-induced inhibition of gap-junctional intercellular communication. Biochem Biophys Res Commun. 2000;275:804–809
  116. Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia. 2000;2:291–299
  117. Lin HY, Shih A, Davis FB, Tang HY, Martino LJ, Bennett JA, et al. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol. 2002;168:748–755
  118. Adhami VM, Afaq F, Ahmad N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun. 2001;288:579–585
  119. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001;268:2764–2772
  120. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000;14:1553–1577
  121. Gu W, Luo J, Brooks CL, Nikolaev AY, Li M. Dynamics of the p53 acetylation pathway. Novartis Found Symp. 2004;259:197–205[discussion 205–197, 223–195]
  122. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 2000;20:3224–3233
  123. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell. 2001;12:1315–1328
  124. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274:36031–36034
  125. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis — the p53 network. J Cell Sci. 2003;116:4077–4085
  126. Kim YA, Lee WH, Choi TH, Rhee SH, Park KY, Choi YH. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol. 2003;23:1143–1149
  127. Narayanan BA, Narayanan NK, Re GG, Nixon DW. Differential expression of genes induced by resveratrol in LNCaP cells: p53-mediated molecular targets. Int J Cancer. 2003;104:204–212
  128. Babich H, Reisbaum AG, Zuckerbraun HL. In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett. 2000;114:143–153
  129. Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant. 2000;25:639–645
  130. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 1998;92:996–1002
  131. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001;61:1604–1610
  132. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 2003;22:469–480
  133. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM, Meadows GG. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 2003;190:157–163
  134. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24:300–303
  135. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci. 2003;23:8586–8595
  136. Silverman ES, Du J, Williams AJ, Wadgaonkar R, Drazen JM, Collins T. cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional co-activators of early growth response factor-1 (Egr-1). Biochem J. 1998;336(Pt. 1):183–189
  137. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol. 2000;2:E65–E67
  138. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett. 2002;529:122–125
  139. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998;421:277–279
  140. Sun NJ, Woo SH, Cassady JM, Snapka RM. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998;61:362–366
  141. Cho DI, Koo NY, Chung WJ, Kim TS, Ryu SY, Im SY, et al. Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action. Life Sci. 2002;71:2071–2082
  142. Fesik SW. Insights into programmed cell death through structural biology. Cell. 2000;103:273–282
  143. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 2001;15:1613–1615
  144. Park JW, Choi YJ, Suh SI, Baek WK, Suh MH, Jin IN, et al. Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis. 2001;22:1633–1639
  145. Pellecchia M, Reed JC. Inhibition of antiapoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr Pharm Des. 2004;10:1387–1398
  146. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003;278:41482–41490
  147. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–8589
  148. Deveraux QL, Reed JC. IAP family proteins — suppressors of apoptosis. Genes Dev. 1999;13:239–252
  149. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003;22:2934–2947
  150. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004;279:40511–40520
  151. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the antiapoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–3257
  152. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825–2837
  153. Hayashibara T, Yamada Y, Nakayama S, Harasawa H, Tsuruda K, Sugahara K, et al. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer. 2002;44:193–201
  154. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J. 2003;22:3910–3918
  155. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003;22:1313–1324
  156. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell. 2002;9:625–636
  157. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004;5:392–401
  158. Chinenov Y, Kerppola TK. Close encounters of many kinds: fos–Jun interactions that mediate transcription regulatory specificity. Oncogene. 2001;20:2438–2452
  159. Shen F, Chen SJ, Dong XJ, Zhong H, Ti LY, Cheng GF. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J Asian Nat Prod Res. 2003;5:151–157
  160. Jang JH, Surh YJ. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res. 2001;496:181–190
  161. Manna SK, Mukhopadhyay A, Aggarwal BB. IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol. 2000;165:4927–4934
  162. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 2004;59:214–225
  163. Pellegatta F, Bertelli AA, Staels B, Duhem C, Fulgenzi A, Ferrero ME. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am J Clin Nutr. 2003;77:1220–1228
  164. Stewart JR, Christman KL, O'Brian CA. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol. 2000;60:1355–1359
  165. Storz P, Doppler H, Toker A. Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. Mol Cell Biol. 2004;24:2614–2626
  166. Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, et al. The design and biological properties of potent and selective inhibitors of protein kinase C. Biochem Soc Trans. 1992;20:419–425
  167. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta. 2003;1637:59–69
  168. Storz P, Doeppler H, Toker A. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappa-B. Mol Pharmacol. 2004;66:870–879
  169. Stewart JR, Ward NE, Ioannides CG, O'Brian CA. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry. 1999;38:13244–13251
  170. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196
  171. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000;14:1021–1026
  172. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305:390–392
  173. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369–2380
  174. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–159
  175. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–148
  176. Carleton M, Haks MC, Smeele SA, Jones A, Belkowski SM, Berger MA, et al. Early growth response transcription factors are required for development of CD4(−)CD8(−) thymocytes to the CD4(+)CD8(+) stage. J Immunol. 2002;168:1649–1658
  177. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287–292
  178. Schwachtgen JL, Houston P, Campbell C, Sukhatme V, Braddock M. Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. J Clin Invest. 1998;101:2540–2549
  179. Granet C, Boutahar N, Vico L, Alexandre C, Lafage-Proust MH. MAPK and SRC-kinases control EGR-1 and NF-kappa B inductions by changes in mechanical environment in osteoblasts. Biochem Biophys Res Commun. 2001;284:622–631
  180. Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 2003;278:23360–23368
  181. Quinones A, Dobberstein KU, Rainov NG. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci. 2003;72:2975–2992
  182. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 2003;17:2339–2341
  183. Sala G, Minutolo F, Macchia M, Sacchi N, Ghidoni R. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drugs Exp Clin Res. 2003;29:263–269
  184. Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 2003;16:1642–1651
  185. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004;317:269–275
  186. Lu J, Ho CH, Ghai G, Chen KY. Resveratrol analog, 3,4,5,4′-tetrahydroxystilbene, differentially induces proapoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis. 2001;22:321–328
  187. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun. 1998;253:859–863
  188. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1. NF-kappa B and Pdcd4. Trends Mol Med. 2003;9:36–41
  189. Ahmad KA, Clement MV, Pervaiz S. Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induced apoptosis. Ann N Y Acad Sci. 2003;1010:365–373
  190. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18:775–794
  191. Clement MV, Pervaiz S. Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Free Radic Res. 1999;30:247–252
  192. Pervaiz S, Ramalingam JK, Hirpara JL, Clement MV. Superoxide anion inhibits drug-induced tumor cell death. FEBS Lett. 1999;459:343–348
  193. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429:771–776
  194. Liu Y, Wang W, Hawley J, Birt DF. Adrenalectomy abrogates reduction of 12-O-tetradecanoylphorbol-13-acetate-induced extracellular signal-regulated protein kinase activity in the epidermis of dietary energy-restricted SENCAR mice: implications of glucocorticoid hormone. Cancer Epidemiol Biomarkers Prev. 2002;11:299–304
  195. Przybyszewski J, Yaktine AL, Duysen E, Blackwood D, Wang W, Au A, et al. Inhibition of phorbol ester-induced AP-1-DNA binding, c-Jun protein and c-jun mRNA by dietary energy restriction is reversed by adrenalectomy in SENCAR mouse epidermis. Carcinogenesis. 2001;22:1421–1427
  196. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst. 2003;95:1747–1757
  197. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–299

PII: S0955-2863(05)00035-5

doi: 10.1016/j.jnutbio.2005.01.017

The Journal of Nutritional Biochemistry
Volume 16, Issue 8 , Pages 449-466 , August 2005

Article Tools

* Image Usage & Resolution